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Accepted 27 October 2015Paraoxonase 1 (PON1) is an enzyme that prevents the peroxidation of lipoprotein and cell
membranes. Our hypothesis is that the effect of the PON1 T(−107)C polymorphism on
serum PON1 activity in healthy adult women is dependent on their fatty acid intake profile.
This study included women (n = 39) who completed a food frequency questionnaire. Fatty
acid intake was estimated based on the interview and a nutrient reference table. Blood
samples were collected for genotyping and to measure serum PON1 activity. Serum PON1
activity was different among genotypes and was higher for women of the CC genotype (P <
.001). Women in the study were categorized in 2 groups according to the median nutrient
intake. Overall, there was a difference (P < .05) in serum PON1 activity between the CC and
TT genotypes in women ingesting either above or below the median total fat, saturated
fatty acids, monounsaturated fatty acids, polyunsaturated fatty acids, omega 3 (n-3) and
omega 6 (n-6; P < .05). However, genotype effects on serum PON1 activity were not observed
in women ingesting below the median (15:1) ratio of n-6/n-3 (P > .05) but were observed in
women ingesting above the ratio of n-6/n-3 (P < .05). This is partly because women of the CC
genotype had decreased PON1 activity when ingesting a lower ratio of n-6/n-3 diet (P < .05),
while women of the TT genotype had increased PON1 activity (P < .05). In conclusion, the
overall presence of the C allele was associated with increased serum PON1 activity,
although a diet with high saturated fatty acid or a low ratio of n-6/n-3 reduced PON1 activity
in women with the CC genotype.
© 2016 Elsevier Inc. All rights reserved.Keywords:
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Fig. 1 – Flowchart for subject selection in the study.
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Paraoxonase 1 (PON1) is an enzyme that is mainly associated
with high-density lipoproteins (HDL), synthesized in the liver,
and released in the blood stream [1,2]. PON1 has antioxidant
activity and is able to hydrolyze lipid peroxides, catalyzing the
breakdown of oxidized phospholipids from low-density lipo-
protein (LDL) [3]. Therefore, PON1 plays an important role in
lipid metabolism, preventing atherosclerotic plaque forma-
tion [4,5]. Lower serum PON1 activity is observed in patients
with cardiovascular diseases [6]. In general, atherosclerotic
plaque formation is slower in women than in men, but post-
menopause plaque formation is faster and highly dependent
on pre-menopausal risk factors [7]. Among the risk factors,
polycystic ovarian syndrome is associated with decreased
serum PON1 activity and an increased incidence of cardio-
vascular disease [8,9].
There are over 160 single nucleotide polymorphisms (SNPs)
described in the PON1 gene [4]. Two important SNPs are located
in the coding region of the gene, at codons55 (L55M) [10] and192
(Q192R) [11]. Both SNPs are associatedwith serumPON1 activity
and the chance of developing cardiovascular disease [12,13].
Another important SNP is located at the promoter region, at the
−107 position, and is referred as T(−107)C (rs705379), affecting
PON1 gene expression and serum activity [6]. The CC genotype
is associated with a 2-fold increased serum PON1 activity, and
its frequency is increased in healthy octogenarians, indicating
an association with the overall antioxidant capacity and aging
diseases [14]. The TT genotype is associated with low serum
PON1 activity and an increased risk of coronary artery disease
[15]. The PON1 T(−107)C SNP is one of the most important
factors affecting serum PON1 activity. It accounts for approxi-
mately 12% of the serumactivity variation between individuals,
contributing more than other SNPs, even in combination with
other dietary factors [16]. Therefore, this was the SNP of choice
for the present study.
In addition to genetic factors, numerous environmental
factors, including diet, have been associated with PON1
activity [16–18]. A recent study demonstrated that the
consumption of fatty acids and cholesterol accounts for
approximately 6% of the variance in serum PON1 activity
[16]. Other factors, such as age, gender, smoking and alcohol
consumption, are responsible for approximately 11% of the
variance in PON1 serum activity [16]. A positive association
between the intake of cholesterol and fatty acids with serum
PON1 activity has been found in previous studies [19,20]. In
contrast, others have found no association between PON1
activity and the daily intake of lipids and saturated fatty acids
(SFA) [21] or have even found a negative effect of SFA and
cholesterol on PON1 activity [22]. These studies indicate that,
although there are reports linking nutrient intake and PON1
activity, there is still some controversy, which may be
elucidated by gene-nutrient interaction studies.
Based on the evidence presented, our hypothesis is that
the effect of the fatty acid intake on serum PON1 activity in
healthy adult women is dependent on the genotype. There-
fore, we aimed to observe the effect of the T(−107)C SNP,
located at the PON1 gene promoter, on serum PON1 activity in
healthy women according to the intake profile of fatty acids.To accomplish this, a food frequency questionnaire was
administered to a group of women to estimate their nutrient
intake, and blood samples were collected for determining the
PON1 genotype and serum PON1 enzyme activity. This gene-
nutrient interaction study will help us to arrive at a better
understanding of how the modulation of PON1 activity by
nutrient intake is associated with this important PON1
promoter SNP.2. Methods and materials
2.1. Design and population
A cross-sectional study of healthy women (n = 39) between 18
and 60 years old, regardless of nutritional status, was conduct-
ed at the gynecology section from the Federal University of
Pelotas. Subject selection is depicted in Fig. 1. We excluded
women younger than 18 years, those using any medicine that
could compromise vascular function and the hypothalamic-
pituitary-gonadal axis, and pregnant women [22]. The study
was approved by the Federal University of Pelotas Ethics
Committee. All subjects gave written, informed consent.
2.2. Food consumption and anthropometric measures
To estimate nutrient intake, a previously validated food
frequency questionnaire was applied [23]. The survey asked
about the average frequency of intake over the previous
month of specified portions of 67 foods. From the question-
naires, the daily caloric intake (kcal/d), total fat intake (g/d),
ig. 2 – Paraoxonase (PON1) activity (U/mL) amongwomen (n =
9) from the CC, CT, and TT genotypes for the PON1 T(−107)C
olymorphism. The data are presented as the means ± SEM.
Different letters indicate significant differences at P < .05.
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saturated fatty acid (PUFA) intake as a percentage of the total
daily intake of fat (%); and omega-3 (n-3; g/d) and −6 (n-6; g/d)
and the ratio of n-6/n-3 were estimated according to the
nutrient value of each food component [24].
Anthropometric measurements, including weight (kg),
height (m), body mass index (BMI) and abdominal circumfer-
ence (cm), were performed according to previously
established criteria [25]. BMI was calculated according to the
formula [BMI = weight/(height*height)]. Waist circumference
was obtained as an estimation of central obesity and was
measured approximately 2 inches above the navel; lesser
curvature was located between the ribs and the iliac crest [25].
2.3. Blood collection and analyzes
Blood collection was performed after the interview in a
clinical analysis laboratory. Approximately 12 mL of blood
without anticoagulant and 5 mL of blood with EDTA were
collected by venipuncture after 12 hours of fasting. The serum
samples were processed immediately, and the sera were
analyzed in an automated equipment for total cholesterol
(Biosystems, RJ, Brazil), triglycerides (TG; Doles, GO, Brazil),
glucose (Biosystems, RJ, Brazil) and HDL (Biosystems, RJ,
Brazil), following the manufacturers' instructions. The LDL
concentration was estimated using the Friedewald equation:
(total cholesterol – HDL) – TG/5 [26].
PON1 activity was measured by its arylesterase activity as
previously established [27]. Arylesterase activity was mea-
sured by the phenol formation rate by monitoring the
increase in absorbance at 270 nm and 25°C. The working
reagent consisted of 20 mmol/L Tris/HCl, pH 8.0, containing 1
mmol/L of CaCl2 and 4 mmol/L phenyl acetate as substrate.
The samples were diluted 1:3 in a 20 mmol/L Tris/HCl buffer
and were added to the working reagent and the change in
absorbance was recorded for 60 seconds. The activity was
expressed in kU/L, based on the phenol extinction coefficient.
2.4. DNA extraction and analysis of the PON1 T(−107)C SNP
For genomic DNA extraction, a previously described solution-
based salting out protocol for whole blood samples was used
[28]. A 240-bp fragment from the promoter region of the PON1
gene was amplified by PCR, and digestion with the BrsBI
restriction enzyme (New England Bio Labs, Cambridge, UK)
was performed as previously described [14]. PCR was performed
in 35 cycles (5 min at 94°C followed by 45 s at 94°C, 45 s at 67°C,
and 45 s at 72°C) with a final extension of 5minutes at 72°C. The
following primers were used: forward AGCTAGCTGCG
GACCCGGCGGGGAGGaG and reverse GGCTGCAGCCCTCACCA
CAACCC. The lowercase letter in the forward primer indicates a
pairing error introducing at a restriction site for the BsrBI
enzyme because there is no specific restriction site for cutting
the original DNA sequence. After digestion for 2 hours at 37°C
with 3 U of BrsBI, the DNA fragments were separated by
electrophoresis on a 3% agarose gel stained with SYBR Safe
(Applied Biosystems, Foster City, CA, USA). The presence of the
C allele was identified by fragments of 28 and 212 bp, while the
presence of the T allele resulted in an undigested 240-bp
fragment, as previously established [14].2.5. Statistical analyses
Statistical analyses were performed using SAS 9.2 software
(SAS Institute Inc, Cary, NC, USA). The data are presented as
the means ± SEM. The sample size was calculated using the
power procedure for 1-way analysis of variance (ANOVA),
considering P < .05 with a power of 0.80 and using the
reference PON1 activity from Campo et al [14]. In addition, the
actual sample size was doubled to allow enough power when
dividing individuals in subgroups by the median nutrient
intake. One-way ANOVA was performed to analyze the effect
of genotype on PON1 activity and the HDL, LDL, cholesterol,
TG, and glucose concentrations. Age, BMI, and total calorie
intake were used as covariates, and as they had no effect on
the serum PON1 activity, they were excluded from the model.
In addition, the median nutrient intake was calculated, and
individuals were categorized as ingesting above or below the
median for each nutrient. One-way ANOVA was performed to
test for the effect of the genotype in each category. In
addition, the t-test was used to compare the 2 intake
categories (below or above the median) for each genotype
(CC, CT, and TT). The χ2 test was used to test the population
for Hardy-Weinberg equilibrium and also to compare the
genotype distribution with other populations. P values below
.05 were considered statistically significant.3. Results
3.1. The PON1 T(−107)C polymorphism determines PON1
serum activity in women
The frequency of genotypes for the PON1 T(−107)C polymor-
phism for women in the studied population was 30.8% (12/39)
for the CC genotype, 41.0% (16/39) for the CT genotype, and
28.2% (11/39) for the TT genotype. The genotype distribution
was in Hardy-Weinberg equilibrium (P = .26). Serum PON1
activity was different among the three genotypes and was
higher for the CC genotype and lower for the TT genotype (P <
.001; Fig. 2). The genotype distributionwas not different (P = .43)
from that previously reported for European populations.
The serum concentrations of HDL, LDL, cholesterol, TG,
and glucose and BMI and waist circumference are shown inF
3
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cholesterol, triglycerides, glucose or BMI, and waist circum-
ference (P > .05; data not shown).
3.2. Food components can influence PON1 activity depending
on the PON1 T(−107)C genotype
The participants’ daily intake of energy, fat, SFA, MUFA, PUFA,
cholesterol, n-3, and n-6 are presented in Table 1. For the
analysis of the gene-nutrient interaction,womenwere divided
as ingesting below or above the median for each component
and analyzed for the genotype effect in each subgroup.
As stated before, the serum PON1 activity was overall
affected by the genotype, increasing with the presence of the
C allele. When categorizing women in the study by median
nutrient intake, it was possible to observe that some food
components interact with the genotype to affect serum PON1
activity. Overall, there was a difference (P < .05) in serum PON1
activity between the CC and TT genotypes in women
ingesting above and below the median for cholesterol, total
fat, SFA, MUFA, and PUFA (Fig. 3), indicating no gene-nutrient
interaction. However, the serum PON1 activity was lower in
women in the CC genotype ingesting more than 40% of fat
from SFA (P < .05), although no difference was observed for
women of the CT and TT genotypes (Fig. 3).
Serum PON1 activity was also different between the CC
and TT genotypes, independent of the n-3 and n-6 ingestion
level (P < .05, Fig. 4). However, when comparing women
ingesting below (<15:1) and above (>15:1) the median ratio of
n-6/n-3, we observed an effect of the genotype on serum PON1
activity for women ingesting above the median (P < .05), but
no genotype effect for women ingesting below themedian (P >
.05; Fig. 4). In this sense, women of the CC genotype hadTable 1 – The serum lipid profile, age, BMI, waist
circumference, and daily nutrient estimated intake of
women (n = 39) enrolled in the study
Parameter Means ± SEM
Age (y) 41.2 ± 2.4
PON1 (U/mL) 98.4 ± 3.9
HDL (mg/dL) 57.7 ± 2.3
LDL (mg/dL) 129.4 ± 5.5
Cholesterol (mg/dL) 212.8 ± 6.4
Triacylglycerides (mg/dL) 143.3 ± 11.2
Glucose (mg/dL) 88.9 ± 2.5
BMI (kg/m2) 26.8 ± 0.7
WC (cm) 93.4 ± 1.8
Daily nutrient intake
Calories (kcal/d) 2,104.6 ± 90.6
Fat (g/d) 55.5 ± 3.0
SFA (g/d)* 21.1 ± 1.1 (38.5%)
MUFA (g/d)* 14.0 ± 0.8 (25.5%)
PUFA (g/d)* 11.6 ± 0.9 (20.4%)
n-3 (g/d) 0.7 ± 0.0
n-6 (g/d) 10.6 ± 0.9
Ratio of n-6/n-3 16.1 ± 0.6
Cholesterol (mg/d) 268.6 ± 14.8
WC, waist circumference; n-3, omega 3; n-6, omega 6; * indicates
the percentage of SFA, MUFA, and PUFA from total fat intake.increased PON1 activity when ingesting a diet with a higher
ratio of n-6/n-3 (P < .05), while women of the TT genotype had
a reduction in serum PON1 activity (P < .05; Fig. 4).4. Discussion
The PON1 gene promoter polymorphism T(−107)C has a
strong influence on serum PON1 activity, with the CC
genotype associated with the highest levels of serum PON1
activity [6,14,29]. In the present study, this polymorphismwas
studied in women of the Southern Brazil region, with further
indication that the CC genotype is associated with increased
serum PON1 activity. In addition, the genotype distribution
found in the current study was not different from that found
in European populations [14,15,29]. Therefore, we hypothe-
sized that because PON1 activity is also affected by the profile
of fatty acid intake, a gene-nutrient interaction could exist for
this specific SNP in the promoter of the gene. Our hypothesis
was confirmed, and we were able to demonstrate that the
level of fatty acid intake can affect serum PON1 activity
depending on the PON1 T(−107)C genotype.
As stated before, the presence of the C allele had an overall
positive effect on serum PON1 activity. However, for women
ingesting below themedian ratio of n-6/n-3 (<15:1), no effect of
the genotype on serum PON1 activity was observed at all,
while the genotype effect was preserved for women ingesting
above the median ratio of n-6/n-3. This is because of the
ingestion of a ratio of n-6/n-3 below 15:1 reduced serum PON1
activity in women with the CC genotype and increased PON1
activity in carriers of the TT genotype. PUFAs, including n-6
and n-3 fatty acids, are known for inhibiting PON1 activity [30],
and others have shown that the ingestion of arachidonic and
eicosaepentaenoic acids is negatively correlated to serum
PON1 activity [19]. Increased production of free radicals after
n-3 supplementation has been identified as the cause of
decreased serum PON1 activity [31], while some reports
indicate an increased serum PON1 activity after n-3 supple-
mentation [5,32,33]. Nevertheless, our study points to an
important divergent response between women of the CC and
TT genotypes to the ratio of n-6/n-3 intake, and further work is
needed to elucidate this interaction and adjust recommenda-
tions for this group. It should be taken into account that the n-
3 intake of the studied population averaged 0.4 g/d and is well
below the recommended 2 to 4 g/d [34]. The marked change in
the ratio of n-6/n-3 may also be the reason for the contradic-
tory results compared to populations with a higher n-3 intake
or when n-3 is exogenously supplemented. Previous gene-
nutrient interaction studies of n-3:n-6 fatty acid intake have
shown an interaction between diet and 5-lipoxygenase for
intimamedia thickness [35] and between the APOA4, APOA4,
and APOC3 genotypes and the serum lipid profile [36]. It is
important to consider carefully the interactions observed in
the present study due to the small sample size, the fact that
only women were analyzed and, especially, that nutrient
intake was estimated based only on a food frequency
questionnaire and that there were no blood markers for the
level of fatty acid intake. Nonetheless, the present study
suggests an interesting interaction between the gene and
nutrient intake and new studies should be performed.
Fig. 3 – Paraoxonase (PON1) activity (U/mL) of women (n = 39) with the CC, CT, and TT genotypes for the PON1 T(−107)C
polymorphism. The intake groupwas categorized based on themedian intake from the studied population of total fat (g/d) and
the percentage of fat ingestion derived from SFA, MUFA, and PUFA. The data are presented as the means ± SEM. Asterisks
indicate differences between intake categories within the same genotype at the significance level of P < .05. Different letters
indicate differences among genotypes in each intake category at the significance level of P < .05.
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genotype, although it was previously reported that fat intake
is a modulator of serum PON1 activity [19]. In this regard,
although the daily fat intake was within the recommended
range [37], the quality of the ingested fat was compromised.
The intake of SFA was 7.6% above current recommendations
[38], while the intake of MUFA was 6.5% below the recom-
mendations [37]. The PUFA intake was 8.5% and was within
the recommended range [38]. We observed that women of the
CC genotype who ingestedmore than 40% of SFA had reduced
serum PON1 activity compared to women of the CC genotype
ingesting less than 40% of SFA. Previous studies in animal
models suggested that a high-fat diet, rich in cholesterol and
SFA, was linked to reduced serum PON1 activity [30,39,40].
Studies in humans also reported that a Mediterranean diet
increases PON1 activity, while a Western-type diet decreases
PON1 activity [21]. However, other authors have found no
direct association between PON1 activity and cholesterol and
SFA intake [41] or even increased PON1 activity in cholesterol-
and SFA-rich diets [16]. Therefore, it is possible that gene-
nutrient interactions, such as the one observed in our study of
the relationship between PON1 and SFA intake, can be the
source of conflicting results observed elsewhere and should
be further explored in larger populations. In this regard,
another gene-nutrient study has shown a reduction of PON1
activity induced by the intake of a high vegetable diet, which
was greatest among women with the PON1192Arg allele and
PON155Leu/Leu genotype, although interaction with the
PON1T(−107)C was not tested [42]. In the above-mentionedstudy, the high vegetable diet had a higher amount of PUFA
and vitamin C than the low vegetable diet.
Although numerous studies indicate a positive correlation
between serum PON1 activity and HDL [20,43] and a negative
correlation with LDL, TG, and glucose [44,45], we did not find
any associations between these variables and PON1 serum
activity. We also did not find an effect of the genotype on the
serum lipid profile, which is consistent with a previous report
indicating that none of the known PON1 polymorphisms had
a significant effect on the lipid profile [46]. The calorie intake
and BMI of women in this study were 2104.6 kcal/day and 26.8
kg/m2, respectively. These values indicate a slightly over-
weight population [25], although the average reported daily
caloric intake is considered sufficient for the majority of the
population [37]. The BMI and caloric intake results are in
accordance to previous reports of the Brazilian population
[47], indicating that the studied population is representative
of the population weight and consumption behaviors.
In conclusion, the presence of the C allele was associated
with increased serum PON1 activity in adult women in the
southern region of Brazil. A gene-nutrient interaction was
identified and indicated that a diet high in SFA, or with a low
ratio of n-6/n-3, had a negative impact on serum PON1
activity, specifically for carriers of the CC genotype.Conflict of Interest
The authors declare that they have no competing interests.
Fig. 4 – Mean paraoxonase (PON1) activity (U/mL) of women
with the CC, CT, and TT genotypes of the PON1 T(−107)C
polymorphism. The intake group was divided based on the
median intake from the studied population of omega 3 (n-3,
g/d) and omega 6 (n-6, g/d) and the ratio of n-6/n-3. The data
are presented as the means ± SEM. Asterisks indicate
differences between intake categories within the same
genotype (*P < .05, **P < .01). Different letters indicate
differences among genotypes in each intake category at the
significance level of P < .05.
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